Abstract:BACKGROUND: A growing number of studies suggest that lentinan combined with cisplatin thoracic injection for the treatment of lung cancer is an effective combination of traditional Chinese and Western medicine, which has a continuous and beneficial effect on eliminating clinical symptoms and improving cachexia in lung cancer patients. However, whether this treatment is effective and safe for lung cancer patients or not, evidence supporting the effectiveness and safety of this treatment is still incomplete. Besides, there is lack of systematic review to assess the detailed situation (including risk of bias and methodology) of current related clinical studies.OBJECTIVE: This study aimed to evaluate the effectiveness and safety of lentinan combined with cisplatin thoracic injection in the treatment of lung cancer.METHODS: The major databases (Embase, PubMed, the Cochrane Library, China National Knowledge Infrastructure, Chinese Scientific Journals Database [VIP] Database, Chinese Biomedical Literature Service System [SinoMed], and Wanfang Database) were searched from inception to March 1, 2020. Randomized controlled trials (RCTs) of lentinan combined with cisplatin chest injection on patients with non-small cell lung cancer (NSCLC) were identified. Two assessors reviewed each trial independently. The methodological quality of the eligible studies was evaluated according to the Cochrane Collaboration's tool for assessing risk of bias. Both the data extraction and the literature quality screening evaluation were conducted independently by 2 researchers.RESULTS: Totally 17 clinical RCTs were included in this study, involving 1390 patients. Meta-analysis results showed that the clinical efficacy (risk ratio [RR] = 1.34, 95% confidence interval [CI] 1.21-1.48), effective subgroup analysis (RR = 1.51, 95% CI 1.3-1.77), and quality of life (RR = 1.48, 95% CI 1.27-1.72), the differences are statistically significant. In terms of adverse reactions, mainly related to gastrointestinal reactions and bone marrow suppression, the incidence and degree of adverse reactions of lentinan combined with cisplatin thoracic injection group were lower than those of cisplatin thoracic injection group alone.CONCLUSIONS: The current evidence prompted that Lentinan combined with cisplatin in thoracic injection might benefit patients with NSCLC on a certain extent; this systematic review revealed some definite conclusions about the application of Lentinan combined with cisplatin in thoracic injection for NSCLC. Due to the low methodological quality, high risk of bias, and inadequate reporting on clinical data, these results still require verification by a large number of well designed, heterogeneous RCT studies. More rigorous, multicenter, sufficient-sample, and double-blind RCTs are warranted.

Lentinan mitigates pemetrexed chemoresistance by the PI3K/Akt pathway in non-small cell lung cancer

Co-Inhibition Of Glut-1 Expression And The Pi3k/Akt Signaling Pathway To Enhance The Radiosensitivity Of Laryngeal Carcinoma Xenografts In Vivo

Lentinan triggers oxidative stress-mediated anti-inflammatory responses in lung cancer cells

Lentinan Mitigates Therarubicin-Induced Myelosuppression by Activating Bone Marrow-Derived Macrophages in an MAPK/NF-κB-dependent Manner

Lentinan Inhibits Tumor Angiogenesis Via Interferon Γ and in a T Cell Independent Manner

Luteolin enhances drug chemosensitivity by downregulating the FAK/PI3K/AKT pathway in paclitaxel‑resistant esophageal squamous cell carcinoma

Parthenolide Augments the Chemosensitivity of Non-small-Cell Lung Cancer to Cisplatin via the PI3K/AKT Signaling Pathway

Lentinan Regulates Glioma Cell Proliferation and Apoptosis by Activating P53 and Caspases Pathways

Lentinan Enhances the Function of Oxaliplatin on the Esophageal Tumors by Persuading Immunogenic Cell Death

P3.02b-123 Lysimachia Capillipes Capilliposide Inhibits AKT Activation and Restores Sensitivity to Gefitinib in NSCLC with Acquired Gefitinib Resistance

Luteolin is Effective in the Non‐small Cell Lung Cancer Model with L858R/T790M EGF Receptor Mutation and Erlotinib Resistance

A Meta-Analysis of Lentinan Injection Combined with Chemotherapy in the Treatment of Nonsmall Cell Lung Cancer.

Meta-analysis of Efficacy and Safety of Lentinan Injection Combined with Chemotherapy in the Treatment of Non-small Cell Lung Cancer

A novel strategy to enhance inhibition of Hela cervical cancer by combining Lentinus β -glucan and autophagic flux blockage

Abstract A033: Anti-proliferative effects of lentinan, a beta-glucan from shiitake mushroom (lentinula edodes)

Lentinan inhibits cell invasion via M2 polarization of tumor‐associated macrophages and Wnt/β‐catenin signaling in non‐small cell lung cancer

CD133 inhibition via autophagic degradation in pemetrexed-resistant lung cancer cells by GMI, a fungal immunomodulatory protein from Ganoderma microsporum

Peroxisome proliferator-activated receptor improves pemetrexed therapeutic efficacy in non-squamous non-small cell lung cancer

Effect of Lentinan Combined with Docetaxel and Cisplatin on the Proliferation and Apoptosis of Bgc823 Cells

Lentinan combined with cisplatin for the treatment of non-small cell lung cancer

LINC‐PINT Alleviates Lung Cancer Progression Via Sponging Mir‐543 and Inducing PTEN